FIM
LGND icon

Friedberg Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History

Friedberg Investment Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-6,765
Closed -$512K – 71
2017
Q2 		$512K Sell
6,765
-2,885
-30% -$202K 0.22% 74
2017
Q1 		$637K Buy
9,650
+753
+8% +$49.5K 0.27% 77
2016
Q4 		$563K Sell
8,897
-400
-4% -$25.2K 0.26% 79
2016
Q3 		$591K Buy
9,297
+3,510
+61% +$258K 0.25% 83
2016
Q2 		$430K Buy
+5,787
New +$429K 0.2% 82

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Friedberg Investment Management's LGND Position: Q3 2017 in Review

Friedberg Investment Management sold out of Ligand Pharmaceuticals (LGND) in Q3 2017, closing a stake of 6,765 shares — an estimated $512K sold.

Friedberg Investment Management first reported a position in LGND in Q2 2016 and held it in 5 quarters. The position peaked at $637K in Q1 2017. 293 funds tracked by Wall St. Rank hold LGND as of Q3 2017.

  • Friedberg Investment Management reported no remaining Ligand Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Friedberg Investment Management sold 6,765 Ligand Pharmaceuticals shares in Q3 2017, an estimated $512K.
  • Friedberg Investment Management first reported a position in Ligand Pharmaceuticals in Q2 2016 and held it in 5 quarters.
  • Friedberg Investment Management's Ligand Pharmaceuticals position peaked at $637K in Q1 2017.
  • 293 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2017.

Based on Friedberg Investment Management's 13F filing for Q3 2017, filed 8 Nov 2017.